XBiotech Announces Publication of Breakthrough Findings for Potential Role of Interleukin-1 alpha in Risk for Heart Attacks
Findings Demonstrate Ability of MABp1 (Bermekimab) to Block In Vitro Neutrophil Mediated Vascular Endothelial Activation and Thrombosis
AUSTIN, Texas, Aug. 27, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the publication of findings that point toward a white blood cell-derived interleukin-1 alpha (IL-1⍺) as a cause of blood clots that could lead to heart attacks or strokes. The research was headed by a world-leading cardiovascular researcher, Dr. Peter Libby, Mallinckrodt Professor of Medicine at Harvard Medical School and clinical cardiologist at Brigham and Women’s Hospital. Dr. Libby’s team discovered that white blood cells, known as neutrophils, can release IL-1⍺ that could possibly lead to life threatening strokes in patients with heart disease, which offers the potential for new treatment approaches involving XBiotech’s anti-IL-1⍺ antibody, bermekimab.
The findings describe for the first time an intriguing mechanism whereby so called neutrophil extracellular traps (NETs), released from neutrophils, are laden with IL-1⍺ that is capable of activating cells of the artery wall in a way that in turn activates blood clotting mechanisms and recruits further white blood cells. The publication reports work done by Dr. Libby’s colleagues Drs. Folco and Mawson that describes how in certain kinds of heart disease where the blood vessels become partially blocked by atherosclerotic plaques, activation of the blood vessels by IL-1⍺ on NETs could be an important contributing factor of heart attacks. These findings are among the first to provide a clear mechanism by which neutrophils could cause heart attacks, and at the same time offer hope for a treatment by blocking IL-1⍺. These findings also suggest treatment opportunities for other inflammatory diseases in which neutrophils, and more specifically NETs, play a role in disease pathology, such as in cancer, pulmonary, autoimmune, and gastrointestinal diseases.
Dr. Libby stated, “Our data suggest that activation of vascular endothelial cells by NET-associated IL-1⍺ can not only amplify, sustain, and propagate local vascular inflammation; this process may also be involved in promoting thrombosis. We believe these findings may have very important clinical implications.”
John Simard, XBiotech’s President & CEO, commented, “Dr. Libby’s discovery provides a new mechanism by which to understand where and why we might target IL-1⍺ to treat inflammatory diseases. It is a fundamental advance in biology and an exciting day for us.”
Dr. Libby’s findings are published online in a journal of the American Heart Association (AHA). The article titled, Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1α and Cathepsin G, is featured in the August print issue of Arteriosclerosis, Thrombosis, and Vascular Biology .
Coronary artery thrombosis can be caused by either plaque rupture or plaque erosion1. Superficial plaque erosion causes up to one-third of all acute coronary syndromes2 ,3. Erosion-prone atheromatous plaques, rather than lesions with stable or rupture-prone characteristics, associate with neutrophil extracellular traps (NETs)4. The study performed at Dr. Libby’s laboratory probed the influence of NETs on the endothelial cell (EC) functions related to erosion-associated thrombosis. These data show that exposure of human saphenous veins ECs (HSVECs) to NETs increase expression of adhesion molecules on the surface of endothelial cells such as VCAM-1 and ICAM-1, which may participate in atherogenesis. In addition, pre-treatment of NETs with bermekimab, an anti-IL-1⍺-neutralizing antibody, or IL-1R antagonist, but not with an anti-IL-1β-neutralizing antibody, blocked the initiation of VCAM-1, ICAM-1, and TF expression, each of which link to coronary thrombosis5 ,6. In conclusion, NETs increase thrombogenicity in vitro through a response mediated by IL-1⍺. These data point to a potentially important role for bermekimab therapy in treating certain kinds of heart disease and other neutrophil mediated diseases.
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
1 Crea F, Libby P. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment. Circulation 2017;136:1155–1166.
2 Franck G, et al. Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in Mice – Implications for Superficial Erosion. Circ Res 2017;121:31-42.
3 Libby P. Superficial erosion and the precision management of acute coronary syndromes: not one-size-fits-all. Eur Heart J. 2017;38(11):801-803. doi: 10.1093/eurheartj/ehw599.
4 Quillard T et al. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J. 2015 Jun 7;36(22):1394-404. doi: 10.1093/eurheartj/ehv044. Epub 2015 Mar 8.
5 Tousoulis D , et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart. 2003;89(9):993-7.
6 Folco EJ, Mawson TL, Vromman A et al. Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production through Interleukin-1α and Cathepsin G. Arteriosclerosis, Thrombosis, and Vascular Biology 2018; 2018;38:1901-1912.
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Anima Biotech Named U.S. Deal of the Year Winner at Lifestars™ Life Science Awards20.11.2018 16:17 | Pressemelding
Award recognizes the transformative potential of Anima’s $1B+ collaboration with Lilly BERNARDSVILLE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of drugs that specifically control protein translation, has been named winner of the “U.S. Deal of the Year” award at the 2018 Lifestars AwardsTM. “We are delighted to receive this award, which recognizes the power and potential of our Translation Control Therapeutics platform,” said Yochi Slonim, co-founder and chief executive officer of Anima Biotech. “Our deal with Lilly further validates our approach and our partnering strategy of creating exclusive collaborations around our partners’ chosen targets.” “Lifestars presented a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It’s a testament to Anima Biotech’s efforts that this year’s judging faculty commended them in this manner,” said Neil Darkes, Co-CEO, LSX Ltd. And Lifestars. The int
Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics20.11.2018 15:00 | Pressemelding
US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Cernostics, developer of next-generation cancer diagnostics and prognostics, announced that it has received a U.S. Patent and a European Notice to Grant for the company’s TissueCypher® Barrett’s Esophagus Assay, adding protection to previously awarded foundational, platform patents granted in 2014. Earlier this month, Cernostics received notification from the European Patent Office that claims will be issued for its patent entitled “Systems and Compositions for Diagnosing Barrett’s Esophagus and Methods for Using the Same.” This notice comes on the heels of a recent issuance of a corresponding U.S. patent (U.S. Patent No. 10,018,631). Cernostics’ recent patent claims relate to the company’s clinical test for predicting disease progression in patients with BE and assessment of the likelihood that BE may fur
Gratomic Announces Over-Subscription Non-Brokered Private Placement20.11.2018 14:00 | Pressemelding
TORONTO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. (“GRAT” or the “Company”) (TSX-V: GRAT) (FRANKFURT:CB81, WKN:A143MR) is pleased to announce that the offering of a non-brokered private placement announced on November 16, 2018 has been over-subscribed and the Company will be offering up to 20,000,000 working capital units (the “WC Unit”) for up to $2,000,000 (the “Offering”). Each WC Unit is priced at $0.10 and consists of one (1) common share and one (1) common share purchase warrant (“WC Warrant”). Each WC Warrant entitles the holder to purchase one (1) common share (a “WC Warrant Share”) at a price of $0.20 per WC Warrant Share until the earlier of: (i) three (3) years following the Closing of the Offering; and (ii) in the event that the closing price of the Common Shares on the TSX Venture Exchange is at least $0.30 for ten (10) consecutive trading days, and the 10th trading day (the “Final Trading Day”) is at least four (4) months from the Closing Date, the date which is th
Ondot Systems Named One of North America’s Fastest Growing Companies in Deloitte’s 2018 Technology Fast 500™20.11.2018 14:00 | Pressemelding
Ranked Fastest Growing FinTech Company in Silicon Valley with 224 percent revenue growth and over four thousand Financial Institutions now offering its white label service Santa Clara, California, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Ondot Systems, the leading provider of Digital Card Services and Customer Empowerment Solutions, today announced that it was named by Deloitte’s Technology Fast 500TM as the fastest growing Silicon Valley FinTech company, and one of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. A recent report “Accelerating Digital Transformation in Banking” published by Deloitte on results of a survey of 17,100 consumers across 17 countries concluded that leading technology companies have become the gold standard for digital engagement, thus driving a stronger emotional connection for consumers with these brands over their primary banks. If banks want to keep up, they must engineer their digital exper
Patton Delivers IPv6 Services at the Network Edge20.11.2018 13:15 | Pressemelding
Implementing enhanced IPv6 in SmartNode VoIP CPE, Patton supports simplified network architectures and lowers operation and maintenance costs for service providers and enterprises. SmartNode VoIP… More than Just Talk! GAITHERSBURG, Md., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Patton Electronics—doing business as a bricks-and-mortar manufacturer since 1984—has enhanced IPv6 in its SmartNode CPE, the company announced today. Global expansion of the Internet, proliferation of IP endpoint devices, and the burgeoning Internet of Things (IoT) means we will soon run out of IPv4 addresses. The IPv6 standard expands available IP addresses octillion times, or at least 17 billion . Everyone has known that for a long time and the hype has been going on for years. Service providers made plans, and some partially implemented IPv6 in their networks. Carriers like Telefonica and T-MOBILE—and enterprises such as Microsoft—have started the changeover. Many large enterprises also planned on it, but have spotty
SoftServe Achieves ISO 13485 Standard for Medical Device Quality Management Systems20.11.2018 13:00 | Pressemelding
International standard ensures customer and regulatory requirements are consistently met for the lifecycle of medical device products AUSTIN, Texas, Nov. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it has achieved the ISO 13485:2016 standard – an internationally recognized standard that defines quality management system requirements for medical device manufacturers as set by the International Organization for Standardization (ISO). SoftServe implemented and established a quality management system compliant with the requirements of ISO 13485:2016. This activity was verified by third-party audits by Loyd’s Register, an accredited certification company. One critical advantage of the certification is it cultivates a preventative approach to assure software medical device quality versus a reactive approach of inspection and rejection during production. “With software as a medical device and software in a medical device continuing to
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom